Estudo comparativo entre o Bevacizumabe intravitreo e a fotocoagulação a laser com oftalmoscopio binocular indireto na retinopatia da prematuridade

• Autor(a) principal: Marquez, Tatiana Vieira de Brito
• Data de Publicação: 2010
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UFG
• dARK ID: ark:/38995/0013000003j4j
• Texto Completo: http://repositorio.bc.ufg.br/tede/handle/tede/4189
• topic: Bevacizumabe; Laserterapia; Retinopatia da prematuridade; Terapia antiangiogenica; Injeção intravitrea; Bevacizumab; Laser therapy; Retinopathy of prematurity; Intravitreal; Antiangiogenic therapy; CIENCIAS DA SAUDE

OBJECTIVES: To compare the response of bevacizumab and the response of the laser photocoagulation with indirect binocular ophthalmoscope (IBO) in infants with retinopathy of prematurity (ROP) stages II or III. METHODS: Data collection was performed in the neonatal intensive care unit of the Hospital Materno Infantil, from May to November 2009. Preterm infants with ROP stages II or III, with or without the plus disease were included. They were divided into two groups: on group I, an intra-vitreous injection of bevacizumab was performed and on group II, laser photocoagulation with IBO was performed. RESULTS: In group I, from the 20 eyes that underwent the application of bevacizumab, there was total regression of ROP with one application in 14 eyes, being 4 eyes with complete regression with two doses of bevacizumab, and 2 eyes with total regression after two applications of bevacizumab and one application of laser. On group II, from the 20 eyes treated with laser photocoagulation with IBO, there was total regression of ROP with laser therapy in 14 eyes and there was total regression with two laser sessions in 6 eyes. CONCLUSION: Bevacizumab is effective if compared to laser photocoagulation in ROP stages II and III.